Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.
1. A coated stent comprising:
a coating composition comprising an HMG-CoA reductase inhibitor in an effective amount, of about 1 to 50 wt.-%, and a polymeric carrier component;
wherein the polymeric carrier component comprises a polymer selected from polycaprolactone, ethylene-vinyl acetate polymer, and a two-part silicone rubber,
wherein the HMG-CoA reductase inhibitor is selected from the group consisting of cerivastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, pravastatin and mixtures thereof, and
wherein the HMG-CoA reductase inhibitor is released from the coated stent at a rate of >20 μg/ml per day.
2. The coated stent of claim 1 , further comprising a catheter wherein the catheter and the coated stent can be coupled to form a treatment assembly.
3. The coated stent of claim 1 wherein the coating composition comprises about equal parts by weight of the HMG-CoA reductase inhibitor and the first polymeric carrier component.
4. The coated stent of claim 1 further comprises a rapamycin compound.
5. The coated stent of claim 1 which further comprises one or more bioactive compounds are selected from the group consisting of paclitaxel, actinomycin D, rapamycin, and mixtures thereof.
6. The coated stent of claim 1 which further comprises one or more bioactive compounds are selected from the group consisting of analogs of paclitaxel, actinomycin D, rapamycin, and mixtures thereof.